Market Research Logo

Congenital Adrenal Hyperplasia - Market Insights, Epidemiology and Market Forecast-2028

Congenital Adrenal Hyperplasia - Market Insights, Epidemiology and Market Forecast-2028

DelveInsight’s ‘Congenital Adrenal Hyperplasia - Market Insights, Epidemiology and Market Forecast-2028’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Congenital Adrenal Hyperplasia in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.
The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Congenital Adrenal Hyperplasia from 2016 to 2028 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.
Geography Covered
• The United States
• EU5 (Germany, France, Italy, Spain and the United Kingdom)
• Japan
Study Period: 2016-2028
Congenital Adrenal Hyperplasia - Disease Understanding and Treatment Algorithm
CAH stands for “congenital adrenal hyperplasia”. CAH is an inherited condition that affects the adrenal glands and causes a number of specific health issues. ‘Congenital’ means the condition is present at birth. The adrenal glands are cone-shaped organs that sit on top of each kidney. They make a number of hormones necessary for healthy body function. Hyperplasia means ‘overly large’. In people with CAH, the adrenal glands cannot make enough of a hormone called cortisol. As they start working harder in attempts to make more cortisol they increase in size, resulting in hyperplasia. Babies with CAH are born with a number of physical changes. Their adrenal glands are often larger than normal, even at birth. Girls with CAH may be born with external sex organs that appear more masculine than they should. If not treated, both boys and girls will develop early sexual characteristics, well before normal puberty should begin.
The DelveInsight Congenital Adrenal Hyperplasia market report gives the thorough understanding of the Congenital Adrenal Hyperplasia by including details such as disease definition, classification, causes, symptoms, etiology, pathophysiology, genetics and diagnostic trends. It also provides treatment algorithms and treatment guidelines for Congenital Adrenal Hyperplasia in the US, Europe, and Japan.
Congenital Adrenal Hyperplasia Epidemiology
The Congenital Adrenal Hyperplasia epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed and treatable patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report is segmented by Total Prevalent Cases and Prevalent Cases of Classical CAH, Prevalent Cases of Non-Classical CAH and Diagnosed Prevalent Population of Congenital Adrenal Hyperplasia.
According to DelveInsight, the prevalent cases of Congenital Adrenal Hyperplasia was 832,962 in 2016 in 7 MM and, is expected to increase at a CAGR of XX% during the study period i.e., 2016-2028. Among 7MM, United States account for highest prevalent cases of Congenital Adrenal Hyperplasia with 350,329 prevalent cases in 2016. This trend is expected to increase during the study period.
Congenital Adrenal Hyperplasia Drug Chapters
This segment of the Congenital Adrenal Hyperplasia report encloses the detailed analysis of marketed drugs and late stage (Phase-III) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases. This report includes detailed chapters of promising upcoming therapies.
Congenital Adrenal Hyperplasia Market Outlook
The Congenital Adrenal Hyperplasia market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
Congenital Adrenal Hyperplasia market is expected to grow during the forecasted period of 2019-2028 at a CAGR of XX% owing to the launch of few drugs (presently in Phase III and Phase II). Congenital Adrenal Hyperplasia therapeutics market has seen a 7MM sales of USD 45.7 Million in 2016.
Congenital Adrenal Hyperplasia Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2016-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Congenital Adrenal Hyperplasia Report Insights
• Patient Population
• Therapeutic Approaches
• Pipeline Analysis
• Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies
Congenital Adrenal Hyperplasia Report Key Strengths
• 10 Year Forecast
• 7MM Coverage
• Epidemiology Segmentation
• Drugs Uptake
• Highly Analyzed Market
• Key Cross Competition
Congenital Adrenal Hyperplasia Assessment
• Current Treatment Practices
• Unmet Needs
• Detailed Pipeline Product Profiles
• Market Attractiveness
• Market Drivers and Barriers
Key Benefits
• This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving the Congenital Adrenal Hyperplasia market
• Organize sales and marketing efforts by identifying the best opportunities for Congenital Adrenal Hyperplasia market
• To understand the future market competition in the Congenital Adrenal Hyperplasia market.


1. Key Insights
2. CAH Market Overview at a Glance
2.1. Market Share (%) Distribution of CAH in 2017
2.2. Market Share (%) Distribution of CAH in 2028
3. Disease Overview: Congenital Adrenal Hyperplasia
3.1. Introduction
3.2. Classification of Congenital Adrenal Hyperplasia
3.3. Classic Congenital Adrenal Hyperplasia
3.4. Nonclassic Congenital Adrenal Hyperplasia
3.5. Causes and Symptoms
3.6. Pathophysiology of Congenital Adrenal Hyperplasia
3.7. Pathophysiology of NCAH
3.8. Genetics of Congenital Adrenal Hyperplasia
3.9. Diagnosis of Congenital Adrenal Hyperplasia
3.9.1. Differential Diagnosis of Different Forms of CAH
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. 7MM Prevalent Patient Population of Congenital Adrenal Hyperplasia
5. Country Wise-Epidemiology of Congenital Adrenal Hyperplasia
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Total Prevalent Cases of Congenital Adrenal Hyperplasia in the United States
5.1.3. Prevalent Cases of Classic Congenital Adrenal Hyperplasia in the United States
5.1.4. Prevalent Cases of Non-Classic Congenital Adrenal Hyperplasia in the United States
5.1.5. Total Diagnosed Cases of Congenital Adrenal Hyperplasia in the United States
5.2. EU5
5.2.1. Assumptions and Rationale
5.2.2. Germany
5.2.2.1. Total Prevalent Cases of Congenital Adrenal Hyperplasia in Germany
5.2.2.2. Prevalent Cases of Classic Congenital Adrenal Hyperplasia in Germany
5.2.2.3. Prevalent Cases of Non-Classic Congenital Adrenal Hyperplasia in Germany
5.2.2.4. Total Diagnosed Cases of Congenital Adrenal Hyperplasia in Germany
5.2.3. France
5.2.3.1. Total Prevalent Cases of Congenital Adrenal Hyperplasia in France
5.2.3.2. Prevalent Cases of Classic Congenital Adrenal Hyperplasia in France
5.2.3.3. Prevalent Cases of Non-Classic Congenital Adrenal Hyperplasia in France
5.2.3.4. Total Diagnosed Cases of Congenital Adrenal Hyperplasia in France
5.2.4. Italy
5.2.4.1. Total Prevalent Cases of Congenital Adrenal Hyperplasia in Italy
5.2.4.2. Prevalent Cases of Classic Congenital Adrenal Hyperplasia in Italy
5.2.4.3. Prevalent Cases of Non-Classic Congenital Adrenal Hyperplasia in Italy
5.2.4.4. Total Diagnosed Cases of Congenital Adrenal Hyperplasia in Italy
5.2.5. Spain
5.2.5.1. Total Prevalent Cases of Congenital Adrenal Hyperplasia in Spain
5.2.5.2. Prevalent Cases of Classic Congenital Adrenal Hyperplasia in Spain
5.2.5.3. Prevalent Cases of Non-Classic Congenital Adrenal Hyperplasia in Spain
5.2.5.4. Total Diagnosed Cases of Congenital Adrenal Hyperplasia in Spain
5.2.6. United Kingdom
5.2.6.1. Total Prevalent Cases of Congenital Adrenal Hyperplasia in the United Kingdom
5.2.6.2. Prevalent Cases of Classic Congenital Adrenal Hyperplasia in the United Kingdom
5.2.6.3. Prevalent Cases of Non-Classic Congenital Adrenal Hyperplasia in the United Kingdom
5.2.6.4. Total Diagnosed Cases of Congenital Adrenal Hyperplasia in the United Kingdom
5.3. Japan
5.3.1. Assumptions and Rationale
5.3.2. Total Prevalent Cases of Congenital Adrenal Hyperplasia in Japan
5.3.3. Prevalent Cases of Classic Congenital Adrenal Hyperplasia in Japan
5.3.4. Prevalent Cases of Non-Classic Congenital Adrenal Hyperplasia in Japan
5.3.5. Total Diagnosed Cases of Congenital Adrenal Hyperplasia in Japan
6. Current Treatment Practices
6.1. Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase Deficiency: An Endocrine Society* Clinical Practice Guideline
6.1.1. Management of Congenital Adrenal Hyperplasia and Nonclassic Congenital Adrenal Hyperplasia during Pregnancy
6.1.2. Surveillance for Long-Term Complications of CAH and its Treatment
7. Unmet Needs
8. Marketed drugs
8.1. Alkindi: Diurnal
8.1.1. Drug Description
8.1.2. Regulatory Milestones
8.1.3. Advantages & Disadvantages
8.1.4. Clinical Development
8.1.5. Clinical Trials Information
8.1.6. Safety and Efficacy
8.1.7. Product Profile
9. Emerging Therapies
9.1. Key cross competition- Emerging Therapies
9.2. NBI-74788: Neurocrine Biosciences
9.2.1. Product Description
9.2.2. Other Developmental Activities
9.2.3. Clinical Development
9.2.3.1. Clinical Trials Information
9.2.4. Safety and Efficacy
9.2.5. Product Profile
9.3. Chronocort: Diurnal
9.3.1. Product Description
9.3.2. Other Developmental Activities
9.3.3. Clinical Development
9.3.4. Clinical Trials Information
9.3.5. Safety and Efficacy
9.3.6. Product Profile
9.4. Nevanimibe: Milendo Therapeutics
9.4.1. Product Description
9.4.2. Other Developmental Activities
9.4.3. Clinical Development
9.4.4. Clinical Trials Information
9.4.5. Safety and Efficacy
9.4.6. Product Profile
9.5. SPR001: Spruce Biosciences
9.5.1. Product Description
9.5.2. Other Developmental Activities
9.5.3. Clinical Development
9.5.4. Clinical Trials Information
9.5.5. Product Profile
10. Congenital Adrenal Hyperplasia: United States Market Analysis
10.1. Key Findings
10.2. Total Market Size of Congenital Adrenal Hyperplasia in 7MM
11. Market Outlook by Country
12. The United States: Market Outlook
12.1. United States Market Size
12.1.1. Total Market size of Congenital Adrenal Hyperplasia
12.1.2. Congenital Adrenal Hyperplasia Market by Therapies
12.2. EU-5 Countries: Market Outlook
12.2.1. Germany
12.2.1.1. Total Market size of Congenital Adrenal Hyperplasia
12.2.1.2. Congenital Adrenal Hyperplasia Market by Therapies
12.2.2. France
12.2.2.1. Total Market size of Congenital Adrenal Hyperplasia
12.2.2.2. Congenital Adrenal Hyperplasia Market by Therapies
12.2.3. Italy
12.2.3.1. Total Market size of Congenital Adrenal Hyperplasia
12.2.3.2. Congenital Adrenal Hyperplasia Market by Therapies
12.2.4. Spain
12.2.4.1. Total Market size of Congenital Adrenal Hyperplasia
12.2.4.2. Congenital Adrenal Hyperplasia Market by Therapies
12.2.5. United Kingdom
12.2.5.1. Total Market size of Congenital Adrenal Hyperplasia
12.2.5.2. Congenital Adrenal Hyperplasia Market by Therapies
12.3. Japan: Market Outlook
12.3.1. Total Market size of Congenital Adrenal Hyperplasia
12.3.2. Congenital Adrenal Hyperplasia Market by Therapies
13. Market Drivers
14. Market Barriers
15. Appendix
15.1. Report Methodology
16. DelveInsight Capabilities
17. Disclaimer
18. About DelveInsight
Table 1 Evidence based recommendations for the diagnosis of NCAH (Level of evidence A or B)
Table 2 Characteristics of Different Forms of Congenital Adrenal Hyperplasia (CAH)
Table 3 Total Prevalent Patient Population of Congenital Adrenal Hyperplasia in the 7MM (2016-2028)
Table 4 Total Prevalent Cases of Congenital Adrenal Hyperplasia in the US (2016-2028)
Table 5 Prevalent Cases of Classic Congenital Adrenal Hyperplasia in the US (2016-2028)
Table 6 Prevalent Cases of Non-Classic Congenital Adrenal Hyperplasia in the US (2016-2028)
Table 7 Total Diagnosed Cases of Congenital Adrenal Hyperplasia in the US (2016-2028)
Table 8 Total Prevalent Cases of Congenital Adrenal Hyperplasia in Germany (2016-2028)
Table 9 Prevalent Cases of Classic Congenital Adrenal Hyperplasia in Germany (2016-2028)
Table 10 Prevalent Cases of Non-Classic Congenital Adrenal Hyperplasia in Germany (2016-2028)
Table 11 Total Diagnosed Cases of Congenital Adrenal Hyperplasia in Germany (2016-2028)
Table 12 Total Prevalent Cases of Congenital Adrenal Hyperplasia in France (2016-2028)
Table 13 Prevalent Cases of Classic Congenital Adrenal Hyperplasia in France (2016-2028)
Table 14 Prevalent Cases of Non-Classic Congenital Adrenal Hyperplasia in France (2016-2028)
Table 15 Total Diagnosed Cases of Congenital Adrenal Hyperplasia in France (2016-2028)
Table 16 Total Prevalent Cases of Congenital Adrenal Hyperplasia in Italy (2016-2028)
Table 17 Prevalent Cases of Classic Congenital Adrenal Hyperplasia in Italy (2016-2028)
Table 18 Prevalent Cases of Non-Classic Congenital Adrenal Hyperplasia in Italy (2016-2028)
Table 19 Total Diagnosed Cases of Congenital Adrenal Hyperplasia in Italy (2016-2028)
Table 20 Total Prevalent Cases of Congenital Adrenal Hyperplasia in Spain (2016-2028)
Table 21 Prevalent Cases of Classic Congenital Adrenal Hyperplasia in Spain (2016-2028)
Table 22 Prevalent Cases of Non-Classic Congenital Adrenal Hyperplasia in Spain (2016-2028)
Table 23 Total Diagnosed Cases of Congenital Adrenal Hyperplasia in Spain (2016-2028)
Table 24 Total Prevalent Cases of Congenital Adrenal Hyperplasia in the UK (2016-2028)
Table 25 Prevalent Cases of Classic Congenital Adrenal Hyperplasia in the UK (2016-2028)
Table 26 Prevalent Cases of Non-Classic Congenital Adrenal Hyperplasia in the UK (2016-2028)
Table 27 Total Diagnosed Cases of Congenital Adrenal Hyperplasia in the UK (2016-2028)
Table 28 Total Prevalent Cases of Congenital Adrenal Hyperplasia in Japan (2016-2028)
Table 29 Prevalent Cases of Classic Congenital Adrenal Hyperplasia in Japan (2016-2028)
Table 30 Prevalent Cases of Non-Classic Congenital Adrenal Hyperplasia in Japan (2016-2028)
Table 31 Total Diagnosed Cases of Congenital Adrenal Hyperplasia in Japan (2016-2028)
Table 32 Evidence based recommendations for the treatment of NCAH
Table 33 Infacort, Clinical Trial Description, 2018
Table 34 NBI-74788, Clinical Trial Description, 2018
Table 35 Chronocort, Clinical Trial Description, 2018
Table 36 Nivanimibe, Clinical Trial Description, 2018
Table 37 SPR001, Clinical Trial Description, 2018
Table 38 Total Market Size of Congenital Adrenal Hyperplasia in the 7MM (2016-2028)
Table 39 United States Market Size of Congenital Adrenal Hyperplasia in USD Million (2016-2028)
Table 40 United States Market Size of CAH by Therapies in USD Million (2016-2028)
Table 41 Germany Market Size of Congenital Adrenal Hyperplasia in USD Million (2016-2028)
Table 42 Germany Market Size of CAH by Therapies in USD Million (2016-2028)
Table 43 France Market Size of Congenital Adrenal Hyperplasia in USD Million (2016-2028)
Table 44 France Market Size of CAH by Therapies in USD Million (2016-2028)
Table 45 Italy Market Size of Congenital Adrenal Hyperplasia in USD Million (2016-2028)
Table 46 Italy Market Size of CAH by Therapies in USD Million (2016-2028)
Table 47 Spain Market Size of Congenital Adrenal Hyperplasia in USD Million (2016-2028)
Table 48 Spain Market Size of CAH by Therapies in USD Million (2016-2028)
Table 49 United Kingdom Market Size of Congenital Adrenal Hyperplasia in USD Million (2016-2028)
Table 50 United Kingdom Size of CAH by Therapies in USD Million (2016-2028)
Table 51 Japan Market Size of Congenital Adrenal Hyperplasia in USD Million (2016-2028)
Table 52 Japan Size of CAH by Therapies in USD Million (2016-2028)
Figure 1 Genetic organization of CYP21A2 and CYP21A1P
Figure 2 Diagnosis of CAH after infancy
Figure 3 Algorithm for the diagnosis of NCAH. 17-OH progesterone, 17-hydroxyprogesterone
Figure 4 Prevalent Patient Population of Congenital Adrenal Hyperplasia in the 7MM (2016-2028)
Figure 5 Total Prevalent Cases of Congenital Adrenal Hyperplasia in the US (2016-2028)
Figure 6 Prevalent Cases of Classic Congenital Adrenal Hyperplasia in the US (2016-2028)
Figure 7 Prevalent Cases of Non-Classic Congenital Adrenal Hyperplasia in the US (2016-2028)
Figure 8 Total Diagnosed Cases of Congenital Adrenal Hyperplasia in the US (2016-2028)
Figure 9 Total Prevalent Cases of Congenital Adrenal Hyperplasia in Germany (2016-2028)
Figure 10 Prevalent Cases of Classic Congenital Adrenal Hyperplasia in Germany (2016-2028)
Figure 11 Prevalent Cases of Non-Classic Congenital Adrenal Hyperplasia in Germany (2016-2028)
Figure 12 Total Diagnosed Cases of Congenital Adrenal Hyperplasia in Germany (2016-2028)
Figure 13 Total Prevalent Cases of Congenital Adrenal Hyperplasia in France (2016-2028)
Figure 14 Prevalent Cases of Classic Congenital Adrenal Hyperplasia in France (2016-2028)
Figure 15 Prevalent Cases of Non-Classic Congenital Adrenal Hyperplasia in France (2016-2028)
Figure 16 Total Diagnosed Cases of Congenital Adrenal Hyperplasia in France (2016-2028)
Figure 17 Total Prevalent Cases of Congenital Adrenal Hyperplasia in Italy (2016-2028)
Figure 18 Prevalent Cases of Classic Congenital Adrenal Hyperplasia in Italy (2016-2028)
Figure 19 Prevalent Cases of Non-Classic Congenital Adrenal Hyperplasia in Italy (2016-2028)
Figure 20 Total Diagnosed Cases of Congenital Adrenal Hyperplasia in Italy (2016-2028)
Figure 21 Total Prevalent Cases of Congenital Adrenal Hyperplasia in Spain (2016-2028)
Figure 22 Prevalent Cases of Classic Congenital Adrenal Hyperplasia in Spain (2016-2028)
Figure 23 Prevalent Cases of Non-Classic Congenital Adrenal Hyperplasia in Spain (2016-2028)
Figure 24 Total Diagnosed Cases of Congenital Adrenal Hyperplasia in Spain (2016-2028)
Figure 25 Total Prevalent Cases of Congenital Adrenal Hyperplasia in the UK (2016-2028)
Figure 26 Prevalent Cases of Classic Congenital Adrenal Hyperplasia in the UK (2016-2028)
Figure 27 Prevalent Cases of Non-Classic Congenital Adrenal Hyperplasia in the UK (2016-2028)
Figure 28 Total Diagnosed Cases of Congenital Adrenal Hyperplasia in the UK (2016-2028)
Figure 29 Total Prevalent Cases of Congenital Adrenal Hyperplasia in Japan (2016-2028)
Figure 30 Prevalent Cases of Classic Congenital Adrenal Hyperplasia in Japan (2016-2028)
Figure 31 Prevalent Cases of Non-Classic Congenital Adrenal Hyperplasia in Japan (2016-2028)
Figure 32 Total Diagnosed Cases of Congenital Adrenal Hyperplasia in Japan (2016-2028)
Figure 33 Unmet Needs for Congenital Adrenal Hyperplasia
Figure 34 Total Market Size of Congenital Adrenal Hyperplasia in the 7MM (2016-2028)
Figure 35 United States Market Size of Congenital Adrenal Hyperplasia in USD Million (2016-2028)
Figure 36 United States Market Size of CAH by Therapies in USD Million (2016-2028)
Figure 37 Germany Market Size of Congenital Adrenal Hyperplasia in USD Million (2016-2028)
Figure 38 Germany Market Size of CAH by Therapies in USD Million (2016-2028)
Figure 39 France Market Size of Congenital Adrenal Hyperplasia in USD Million (2016-2028)
Figure 40 France Market Size of CAH by Therapies in USD Million (2016-2028)
Figure 41 Italy Market Size of Congenital Adrenal Hyperplasia in USD Million (2016-2028)
Figure 42 Italy Market Size of CAH by Therapies in USD Million (2016-2028)
Figure 43 Spain Market Size of Congenital Adrenal Hyperplasia in USD Million (2016-2028)
Figure 44 Spain Market Size of CAH by Therapies in USD Million (2016-2028)
Figure 45 United Kingdom Market Size of Congenital Adrenal Hyperplasia in USD Million (2016-2028)
Figure 46 United Kingdom Market Size of CAH by Therapies in USD Million (2016-2028)
Figure 47 Japan Market Size of Congenital Adrenal Hyperplasia in USD Million (2016-2028)
Figure 48 Japan Market Size of CAH by Therapies in USD Million (2016-2028)
Figure 49 Market Drivers
Figure 50 Market Barriers

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report